Skip to main content
. Author manuscript; available in PMC: 2012 Mar 4.
Published in final edited form as: Cell Stem Cell. 2011 Mar 4;8(3):309–317. doi: 10.1016/j.stem.2011.01.012

Figure 2. Leukocyte costimulatory molecule blockade permits engraftment of differentiated hESC-derivatives.

Figure 2

Mean fluorescence intensity of MHC antigens, pluripotency (SSEA-4), and endothelial (CD31) markers on (a) in vivo differentiated hESCs isolated from explanted teratoma and (b) in vitro differentiated hESC-ECs. Filled histograms represent isotype control antibodies. (c) BLI of the survival of in vivo differentiated hESCs transplanted into immunodeficient (NOD/SCID) and immunocompetent (BALB/) mice that received either costimulatory blockade (COSTIM) or no immunosuppressive treatment, n = 3–4 per group. (d) Bioluminescence photon intensities representing the survival of in vitro differentiated hESC-ECs after transplantation into immunodeficient, costimulatory blockade (COSTIM) treated, or non-treated immunocompetent (BALB/c) mice, n = 4 per group, *P<0.05. For additional engraftment data regarding differentiated ESCs, see Figure S2.